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Abstract
Background: The aim of the study is to investigate whether body mass index (BMI) affected pathological
characteristics and biochemical recurrence (BCR) of prostate cancer after radical prostatectomy in Chinese men.
Methods: Medical records of 211 Chinese patients who underwent radical prostatectomy between 2006 and 2014
were retrospectively reviewed, with follow-up time of 24.5 ± 27.0 months. Multivariate logistic and Cox regression
analyses were applied to address the impact of BMI on adverse pathological outcomes and BCR following
prostatectomy. A meta-analysis of published studies from MEDLINE or EMBASE was conducted to determine the
relationship between BMI and BCR following prostatectomy among Asian populations.
Results: Higher BMI was positively correlated with higher biopsy Gleason score (odds ratios (OR) 1.163, 95 %
confidence interval (CI) 1.023–1.322, P = 0.021) and pathological Gleason score (OR 1.220, 95 % CI 1.056–1.410,
P = 0.007) in multivariate analysis. BCR was detected in 48 patients (22.7 %). Multivariate Cox proportional hazards
analysis revealed that higher BMI (hazard ratio (HR) 1.145, 95 % CI 1.029–1.273, P = 0.013) and prostate-specific
antigen (HR 1.659, 95 % CI 1.102–2.497, P = 0.015) levels were independent predictors of BCR. The meta-analysis
enrolled eight Asian studies of 4145 patients treated by radical prostatectomy. Based on random-effects approach, a
5 kg/m2 increase in BMI was correlated with 28 % higher risk of BCR (HR 1.22, 95 % CI 0.86–1.72) without statistical
significance.
Conclusions: The present study suggested that higher BMI was an independent risk factor for a higher Gleason
score, as well as an independent predictor of BCR after radical prostatectomy in Chinese patients. Meta-analysis of
Asian studies also indicated that obese patients, although without statistical significance, might be more likely to
suffer from BCR.
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Background
Obesity, as a growing public health concern around the
world, was linked to the development and progression of
various cancers [1]. However, the association between
prostate cancer and obesity, generally measured by body
mass index (BMI), remained controversial [2]. Some pre-
vious studies revealed a significant association between
obesity and a higher incidence of prostate cancer (PCa)
[3], worse pathologic outcome [4], and higher incidence
of cancer-specific mortality [5]. However, other re-
searches failed to find such an obvious association be-
tween obesity and PCa [6, 7].
Attributed to the westernization of lifestyle and daily
diet, the prevalence of obesity as well as prostate cancer
was increasing rapidly in Asia (especially in China,
Japan, and Korea) in the past few decades. However, the
researches into the relationship between BMI and differ-
ent clinicopathological characteristics and treatment out-
comes in PCa patients after radical prostatectomy (RP)
remained rare and inconsistent in Asia [8–10].
Therefore, we conducted a retrospective cohort study
to evaluate the impact of BMI on different clinicopatho-
logical features and biochemical recurrences (BCR) after
RP in Chinese PCa patients. Meanwhile, we carried out
a systematic review and meta-analysis of previous stud-
ies discussing the relationship between obesity and BCR
in Asia. The significance of this analysis could be far-
reaching, as proper strategies towards patients with dif-
ferent BMI might help improve the prognosis of PCa
and cost-effectiveness of postoperative treatment.
Methods
Study population
A total of 213 consecutive patients with clinically localized
PCa underwent RP from February 2006 to December
2014 at our institute. The study was approved by the insti-
tutional review board, and written informed consent forms
were signed by all patients prior to their inclusion of the
study. No patient had a history of prostate surgery, hor-
monal therapy, chemotherapy, or radiation therapy. All
patients in the study were operated on by two urologists
with more than 10 years’ experience in prostatectomy.
Two patients were excluded from further analysis because
of missing BMI data. RP was achieved using either open
(18 patients) or laparoscopic (193 patients) approach.
Clinicopathological characteristics
Data assessed included patient age at surgery, BMI, pre-
operative prostate-specific antigen (PSA) level, digital
rectal examination (DRE) outcomes, biopsy Gleason score,
clinical stage, prostate volume (PV), prostate nodule
assessed via preoperative transrectal ultrasound (TRUS),
pathological Gleason score, surgical margin status, local in-
vasion status, lymph node involvement, and postoperative
follow-up PSA data. BMI (kg/m2) was calculated as weight
(kg) divided by the square of height (m), and all patients’
height and weight information were recorded preopera-
tively. The patients were categorized into three groups:
normal weight group (BMI <23 kg/m2), overweight group
(BMI 23–24.9 kg/m2), and obese group (BMI ≥25 kg/m2)
on the basis of Asia-Pacific criteria of obesity. Pathological
evaluation of biopsy and surgical specimens was per-
formed according to the Gleason grading system and the
2002 TNM classification. All of the biopsy and patho-
logical specimens were obtained and evaluated in the
same histopathology lab in our institute. All of the patho-
logical results were confirmed by senior pathologists who
specialized in urological pathology.
The association of different BMI categories with clini-
copathological characteristics and BCR was examined.
After surgery, PSA measurements were performed every
3 months for the first year and thereafter every 3 to
6 months. The date of biochemical recurrence was de-
fined as when the serum PSA level exceeded 0.2 ng/ml,
or salvage therapy was initiated even if PSA did not ex-
ceed 0.2 ng/ml.
Statistical analysis
We assessed differences in clinicopathological character-
istics across BMI categories, using the Kruskal-Wallis
test for continuous variables and the chi-squared test for
categorical variables. PSA and PV were analyzed after
logarithmic transformations because these variables were
not normally distributed. Odds ratios (OR) and 95 %
confidence intervals (CI) for adverse pathological out-
comes were estimated for categorical BMI using logistic
regression analysis with or without adjusting for patient
age, PSA, PV, clinical stage, and biopsy Gleason score.
BCR-free survival was determined using Kaplan-Meier
plots and log-rank test. Univariate and multivariate Cox
proportional hazards regression models were adopted to
find out the independent risk factor that predicted BCR.
Statistical analyses were performed using the SPSS ver-
sion 21 (SPSS, Chicago, IL, USA). Statistical significance
was defined as a two-tailed P < 0.05.
Systematic review and meta-analysis
We searched the MEDLINE and EMBASE databases on
April 1, 2015, for English-written studies discussing the
relationship between BCR and obesity in Asian popula-
tions. The search queries were as follows: (“obesity” or
“body mass index” or “BMI”) and (prostate cancer) and
(radical prostatectomy) and (“recurrence” or “progres-
sion” or “failure”).
Two investigators (Bai and Hu) assessed the eligibility
of each study independently. Only clinical studies that
were conducted in Asia with direct comparison between
BMI and BCR following RP were incorporated in the
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review. We excluded reviews, editorials, meta-analysis,
non-human studies, non-English-written papers, and
studies for other disease settings. Data extracted from
each study were as follows: title, authors, journal, publi-
cation year, study period, study population, treatment
method, duration of follow-up, BMI categories, hazard
ratio (HR) estimates with corresponding 95 % CI, and
adjusted confounders in multivariate analysis. HR esti-
mates across different categorical or continuous BMI
were converted to the unified estimate for a 5 kg/m2 in-
crease in BMI using the method stated in our previous
study [11]. Unless otherwise stated, we used the most
adjusted HR from each study. We assessed the hetero-
geneity among studies using Q and I2 statistics. Publica-
tion bias was examined by both Begg’s and Egger’s tests.
Results
BMI and clinical characteristics
The clinicopathological characteristics of patients were
shown in Table 1. In total, 211 patients diagnosed with PCa
with a median age of 68 years were enrolled in this study.
The median BMI was 23.9 kg/m2. In total, 35.5 % of pa-
tients were of normal weight (BMI <23 kg/m2), 33.6 % of
patients were overweight (BMI 23–24.9 kg/m2), and 30.8 %
were obese (BMI >25 kg/m2) according to Asia-Pacific cri-
teria. The median preoperative PSA level was 13.4 ng/ml,
and the median PV was 36.0 ml. When subjects were cate-
gorized according to BMI, patients in the overweight group
had more TRUS nodules compared with other two groups
(chi-squared P = 0.049). No significant differences were ob-
served in age, PSA, PV, and positive DRE findings.
Table 1 Clinicopathological characteristics of patients across different BMI categories
Variables Total subject BMI <23 kg/m2 BMI 23–24.9 kg/m2 BMI ≥25 kg/m2 P valuea
No. of patients (%) 211 75(35.5) 71(33.6) 65(30.8)
BMI (kg/m2) <0.001
Median (IQR) 23.9(3.4) 21.4(2.2) 24.2(1.1) 26.4(1.9)
Range 16.1–30.1 16.1–22.9 23.0–24.9 25.0–30.1
Age (years) 0.373
Median (IQR) 68(8) 67(11) 70(9) 67(8)
Range 47–86 48–86 56–83 47–81
Preoperative PSA (ng/ml) 0.607
Median (IQR) 13.4(11.9) 13.5(15.0) 14(10.3) 11.5(13.1)
Range 1.4–293.3 1.7–293.3 1.4–62.5 2.3–85.6
Prostate volume (ml) 0.326
Median (IQR) 36(16) 37(13) 36(17) 35.5(18)
Range 12–98 13–89 19–98 12–91
Positive DRE finding (%) 68(67.6) 23(31.1) 24(33.8) 21(32.3) 0.94
TRUS nodule (%) 106(50.7) 31(41.9) 44(62.0) 31(48.4) 0.049
Clinical stageb (%) 0.156
cT1 100(47.8) 41(55.4) 28(39.4) 31(48.4)
≥cT2 109(52.2) 33(44.6) 43(60.6) 33(51.6)
Biopsy GS (%) 0.222
≤6 82(38.9) 35(46.7) 25(35.3) 22(33.8)
≥7 129(61.1) 40(53.3) 46(64.8) 43(66.2)
Pathological GS (%) 0.303
≤6 65(30.8) 28(37.3) 20(28.2) 17(26.2)
≥7 146(69.2) 47(62.7) 51(71.8) 48(73.8)
Positive surgical margin (%) 26(12.3) 9(12.0) 4(5.6) 13(20.0) 0.039
Extra capsular invasion (%) 31(14.7) 13(17.3) 8(11.3) 10(15.4) 0.575
Seminal vesicle invasion (%) 24(11.4) 13(17.3) 4(5.6) 7(10.8) 0.083
Lymph node invasion (%) 5(2.4) 2(2.7) 1(1.4) 2(3.1) 0.797
BMI body mass index, IQR interquartile range, PSA prostate-specific antigen, DRE digital rectal examination, TRUS transrectal ultrasound, GS Gleason score
aAll P values were calculated using Kruskal-Wallis test for continuous variables and chi-squared test for categorical variables
bThe clinical stage of two patients was missing according to medical records
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BMI and pathological characteristics
Various preoperative and postoperative pathological
features including biopsy Gleason score, pathological
Gleason score, positive surgical margin, extra capsular
invasion, seminal vesicle invasion, and lymph node in-
volvement were assessed across BMI categories. Obese
patients were at higher risk of having positive surgical
margin (chi-squared P = 0.039). The rest of the patho-
logical characteristics did not differ significantly across
BMI categories (Table 1). In the multivariate regression
model, higher BMI was an independent risk factor for a
higher biopsy Gleason score (OR 1.163, 95 % CI 1.023–
1.322, P = 0.021) and pathological Gleason score (OR
1.220, 95 % CI 1.056–1.410, P = 0.007) (Table 2).
BMI and biochemical recurrence
Of the 211 patients, 48 (22.7 %) experienced BCR during
a follow-up period of 24.5 ± 27.0 months. BCR was ob-
served in 13 of 75 (17.3 %) patients in the normal weight
group, 15 of 71 (21.1 %) patients in the overweight
group, and 20 of 64 (30.8 %) patients in the obese group.
The Kaplan-Meier plot indicated a weak statistically sig-
nificant difference in the incidence of BCR between
three groups (log-rank P = 0.086, Fig. 1). In univariate
Cox proportional hazards analysis (Table 3), higher PSA
(HR 1.509, 95 % CI 1.040–2.190, P = 0.03) and categor-
ical BMI (≥25 kg/m2 vs. <23 kg/m2, HR 2.087, 95 % CI
1.033–4.215, P = 0.04) were both correlated with the
BCR of prostate cancer. In multivariate Cox proportional
hazards analysis (Table 3), higher PSA was still associ-
ated with an increasing HR trend with BCR no matter
whether included BMI was a continuous or categorical
variable (P = 0.015 and 0.011). Continuous BMI was
positively associated with an increased BCR trend (HR
1.145, 95 % CI 1.029–1.273, P = 0.013). Categorical BMI
was positively associated with an increasing HR of BCR
(≥25 kg/m2 vs. <23 kg/m2, HR 2.937, 95 % CI 1.383–
6.237, P = 0.005).
Systematic review and meta-analysis
Our literature search yielded 178 potentially relevant
studies on the relationship between BMI and BCR of
PCa after RP. After screening and full-text assessment,
seven studies conducted in Asia met all eligibility criteria
[8–10, 12–15] and were selected for meta-analysis along
with the current study. As shown in Table 4, all eight
studies followed a total of 4145 Asian PCa patients after
RP from 17 to 58.2 months. Studies were conducted in
Japan (n = 5), Korea (n = 2), and China (n = 1). The
forest plot of meta-analysis showed that a 5 kg/m2 in-
crease in BMI was associated with 22 % higher risk
of BCR (HR 1.22, 95 % CI 0.86–1.72, Fig. 2) but
failed to present statistical significance. Statistical het-
erogeneity was observed among the studies (I2 = 72.9 %).
Table 2 Logistic regression analyses of BMI categories with adverse pathological outcomes
Pathological outcomes BMI (continuous) BMI 23–24.9 kg/m2 vs. <23 kg/m2 BMI ≥25 kg/m2 vs. <23 kg/m2
OR 95 % CI P value OR 95 % CI P value OR 95 % CI P value
Biopsy GS (≥7)
Crude 1.079 0.973–1.196 0.149 1.610 0.828–3.132 0.161 1.710 0.862–3.394 0.125
Multi-adjusted analysisa 1.163 1.023–1.322 0.021 1.940 0.873–4.307 0.104 2.434 1.103–5.371 0.028
Pathological GS (≥7)
Crude 1.090 0.978–1.215 0.121 1.519 0.756–3.051 0.24 1.682 0.815–3.471 0.159
Multi-adjusted analysisa 1.220 1.056–1.410 0.007 1.983 0.828–4.748 0.124 3.379 1.374–8.309 0.008
Positive surgical margin
Crude 1.157 0.987–1.357 0.072 0.438 0.128–1.492 0.187 1.833 0.727–4.620 0.199
Multi-adjusted analysisa 1.169 0.959–1.426 0.121 0.600 0.149–2.406 0.471 1.742 0.550–5.521 0.345
Extra capsular invasion
Crude 1.014 0.881–1.167 0.848 0.606 0.235–1.563 0.3 0.867 0.352–2.135 0.756
Multi-adjusted analysisa 1.145 0.950–1.381 0.156 0.945 0.273–3.267 0.929 1.687 0.551–5.161 0.360
Seminal vesicle invasion
Crude 1.006 0.860–1.177 0.937 0.285 0.088–0.920 0.036 0.576 0.215–1.543 0.272
Multi-adjusted analysisa 1.070 0.865–1.323 0.532 0.414 0.104–1.641 0.209 0.840 0.251–2.810 0.778
Lymph node involvement
Crude 1.004 0.724–1.391 0.983 0.521 0.046–5.880 0.598 1.159 0.159–8.466 0.885
Multi-adjusted analysisa 0.946 0.666–1.344 0.759 0.593 0.038–9.142 0.708 0.922 0.096–8.818 0.944
OR odds ratio, CI confidence interval, other abbreviations as in Table 1
aAdjusted for age, prostate-specific antigen, prostate volume, digital rectal examination outcomes, transrectal ultrasound outcomes, and clinical stage
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Begg’s (P = 0.536) and Egger’s (P = 0.215) tests did not in-
dicate publication bias.
Discussion
The association between BMI and PCa is a global health
concern. Unlike the US where most studies showed a
positive association between greater BMI and increased
aggressiveness of PCa and risk of BCR after prostatec-
tomy [16], insufficient and contradictory data had been
reported on Asian men. Two studies found that higher
BMI independently contributed to biochemical failure of
PCa [8, 12], while several other studies failed to confirm
positive associations between BMI and adverse patho-
logical outcomes or increased BCR [9, 10, 13–15].
As per our knowledge, the present study was the first
to report results in a Chinese population, which indi-
cated that higher BMI was an independent risk factor
for a higher Gleason score, as well as an independent
predictor of BCR after RP. Besides, the present study
conducted a systematic review and meta-analysis of the
association between BMI and BCR after RP in Asian
populations. With a total of 4145 Asian PCa patients
from eight studies, a positive association without statis-
tical significance was detected between BMI and BCR.
Till now, the exact mechanisms underlying the posi-
tive association between obesity and aggressiveness of
PCa were unclear. One possible mechanism for the poor
prognosis of PCa among obese populations was the poor
pathological outcomes of an existing tumor. Previous
studies reported that obesity had a negative impact on
the pathological Gleason score, positive surgical margin,
extra capsular invasion, and lymph node involvement
[17]. It was generally considered that BMI was positively
related to an increased risk of positive surgical margins,
for excessive pelvic fat might affect the surgeon’s vision
and his ability to remove the entire prostate. The results
of our study were partly in line with the previous
researches.
Other possible mechanisms included were that higher
BMI provided a favorable biological microenvironment
for survival and progression of the tumor even after RP.
Men with higher BMI produced a microenvironment
with less testosterone and more estrogen, where PCa
would be less androgen-dependent and more aggressive
[18]. Besides, excessive adiposity inside the body may
have contributed to the growth of tumor by secreting
certain adipokines and inflammatory cytokines [19, 20].
Higher body weight was also associated with increased
gene expression of diverse inflammatory transcripts in
the nuclear factor kappa B pathway, promoting tumor
aggressiveness [21]. Additionally, changes in the meta-
bolic microenvironments of obese men resulted in com-
pensatory hyperinsulinemia as well as increased levels of
insulin-like growth factor 1, both of which were proved
to encourage carcinogenesis and inhibit apoptosis [22].
In the present study, higher BMI was still associated
with BCR even after adjusting for pathological Gleason
score and positive surgical margin, which tended to sup-
port the microenvironment hypothesis.
Unlike the USA or some European countries [11], the
combined HR in the present meta-analysis of Asian stud-
ies failed to adopt a positive association with statistical
significance between BMI and BCR. The discrepancy be-
tween observed findings in Western and Asian popula-
tions might be explained by racial differences and
differences in cancer screening and management strategy.
Fig. 1 Kaplan-Meier plot for biochemical recurrence-free survival across BMI categories
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The average BMI in the Asian population was far lower
than Western counterparts. It was suggested that only
when BMI reached a certain threshold (around 30 kg/m2),
the correlation would be significant with the increased ag-
gressiveness of prostate cancer [13]. Most Asian obese pa-
tients failed to reach such threshold, and there might be
insufficient biological changes in these men to promote
aggressiveness of PCa. Besides, Asian men possessed
higher body fat percentages at the same BMI compared
with Western men [23]. Therefore, an Asian patient might
have quite different internal biological and endocrine
environment from a Western patient at a given BMI.
Moreover, quite different from Western diets, Asian diets
contained higher levels of phytoestrogens, which were
proved to inhibit proliferative and exert pro-apoptotic ef-
fects on prostate tumor via activation of ERβ signaling
[24]. Recently, more researches began to focus on the mo-
lecular basis for ethnic variation and found that several
genetic alterations for prostate carcinogenesis were com-
paratively lower among Asian patients [25].
Selection bias might also contribute to the inconsistent
results. Variations of PCa epidemiology among Asian popu-
lations could be attributed to differences in access to PSA
screening, urology clinics, and available therapies [26]. PSA
screening tests were not generally popularized in Asia; thus,
prostate cancers in Asian patients were generally of higher
stages and pathological scores before surgery. Besides, as
quite a number of elder Asian patients were still concerned
by surgical procedures, they would rather choose different
types of androgen-deprivation therapy instead of RP as a
first-line treatment towards regional prostate cancer [27].
The fluctuation of RP indications within different Asian re-
gions might enhance heterogeneity among studies. Besides,
the high heterogeneity could be further explained by differ-
ent surgery methods (open or laparoscopic) and different
confounders adjusted in the multivariate analyses.
The present study had some limitations. First, our
study was a retrospective study in a tertiary referral hos-
pital in China and thus may not represent the Chinese
population as a whole. Second, since the patient number
and follow-up time were limited, we were not able to
clarify the impact of BMI on long-term prognosis. Third,
the use of BMI was unable to distinguish fat from
muscle. Other parameters like waist circumference,
waist-to-hip ratio, and percentage of visceral adipose tis-
sue [28] might be a better indicator for obesity.
Over the past few decades, the morbidity of obesity and
PCa in Asian countries has shifted towards a more west-
ernized high level [29]. On the contrary, Asian population-
based epidemiological studies discussing the relationship
between obesity and PCa prognosis were still rare. Since
populations across Asian countries shared similar racial
background and living customs, which were quite different
from Western populations, more prospective multicenter
studies would be necessary to elaborate and confirm such
a relationship in Asian populations. Furthermore, other
risk factors [30] such as BMI in early, middle, and late
adulthood, body weight changes before or after surgery,
daily diet components, exercise levels, and unrevealed bio-
logical mechanisms in Asian populations should attract
wider attention from urologists and scientists.
Conclusions
The present cohort study suggested that higher BMI was
an independent risk factor for higher Gleason score, as
Table 3 Univariate and multivariate Cox proportional hazards
analyses for biochemical recurrence-free survival
Variables HR (95 % CI) P value
Univariate
Age 0.976(0.935–1.019) 0.269









Clinical stage 1.308(0.653–2.619) 0.448
Pathological GS (≥7) 1.133(0.597–2.152) 0.702
Positive surgical margin 0.810(0.290–2.263) 0.688
Extra capsular invasion 1.067(0.453–2.514) 0.883
Seminal vesicle invasion 1.994(0.779–5.105) 0.150
Lymph node invasion 2.835(0.872–9.218) 0.083
Multivariate model I
BMI (continuous) 1.145(1.029–1.273) 0.013
Age 0.972(0.929–1.017) 0.225
PSAa 1.659(1.102–2.497) 0.015
Pathological GS (≥7) 0.991(0.512–1.917) 0.978








Pathological GS (≥7) 1.009(0.525–1.938) 0.979
Positive surgical margin 0.428(0.144–1.270) 0.126
HR hazard ratio, other abbreviations as in Tables 1 and 2
aVariables after logarithmic transformation
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Table 4 Overview and characteristics of studies discussing BMI and biochemical recurrence of prostate cancer in Asia
Author, year [Ref] Location Patients BMI (kg/m2) HR (95 % CI) HR per 5 kg/m2 increase
of BMI (95 % CI)
Adjusted
confoundersa
Bai 2015 China N = 211, 2006–2014,
FUT = 24.5 months
Continuous 1.145(1.029–1.273) 1.97(1.15–3.34) 1, 2, 7, 8
Ohwaki 2015 [15] Japan N = 283, 2008–2012,
FUT = 30 months
≥25 vs. <25 0.83(0.40–1.72) 0.83(0.40–1.72) 1, 2, 7, 8
Koo 2014 [10] Korea N = 880, 2005–2011,
FUT = 58.2 months
>23 vs. ≤23 0.63(0.46–0.89) 0.63(0.46–0.89) 2, 5, 6, 7, 8, 14
Hayashi 2014 [12] Japan N = 703, 2002–2009,
FUT = 38.4 months
Continuous 1.07(1.01–1.14) 1.40(1.05–1.93) 1, 2, 7, 8, 9, 10, 15
Narita 2013 [9] Japan N = 1257, 2001–2009,
FUT = 49 months
Continuous 0.987(0.940–1.035) 0.94(0.73–1.19) 1, 2, 7, 8, 9, 10, 11
Lee 2011 [13] Korea N = 512, 2003–2009,
FUT = 37.8 months
Continuous 1.373(0.720–2.326) 4.88(0.19–68.08) 1, 2, 3, 7, 8, 9, 10
Komaru 2010 [14] Japan N = 173, 1997–2007,
FUT = 35 months
≥25 vs. <25 1.398(0.694–2.817) 1.40(0.69–2.82) None
Hisasue 2008 [8] Japan N = 126, 1998–2006,
FUT = 17 months
≥26.4 vs. <26.4 3.53(1.289–9.677) 3.53(1.29–9.68) 1, 2, 4, 7, 8, 12, 13
Ref reference, FUT follow-up time; other abbreviations as in Tables 1, 2, and 3
aAdjusted confounders: 1, age; 2, preoperative PSA; 3, prostate volume; 4, clinical stage; 5, lymphovascular invasion; 6, perineural invasion; 7, pathological Gleason
score; 8, positive surgical margin; 9, extraprostatic extension; 10, seminal vesicle invasion; 11, lymph node involvement; 12, surgical period; 13, total testosterone;
14, pathological T stage; 15, adjuvant radiotherapy
Fig. 2 Forest plot for meta-analysis of identified eight Asian researches
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well as an independent predictor of BCR after RP in
Chinese patients. Meanwhile, the meta-analysis of Asian
studies detected a positive association without statistical
significance between BMI and BCR. Thus, it might be
beneficial for Chinese PCa patients with higher BMI to
be treated more aggressively and followed more closely
after RP.
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